Search research articles
Contact Us
Filters
Showing results (11-20 of 41) with videos related to
Page
of 5
Sort By:
Urology
|
March 1, 2008
Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer
Avishay Sella, Amnon Zisman, Svetlana Kovel, et al.
The Journal of Urology
|
January 17, 2002
Local anesthesia for prostate biopsy by periprostatic lidocaine injection: a double-blind placebo controlled study
Dan Leibovici, Amnon Zisman, Yoram I Siegel, et al.
Clinical Genitourinary Cancer
|
September 18, 2016
Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib
Avishay Sella, M Dror Michaelson, Ewa Matczak, et al.
Anti-Cancer Drugs
|
March 21, 2013
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone
Eduard Vrdoljak, Brian Rini, Manuela Schmidinger, et al.
International Journal of Cancer
|
March 13, 2012
Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients
Ayelet Avraham, Ronit Uhlmann, Aino Shperber, et al.
The Journal of Urology
|
September 18, 2007
The prevalence of malignancy in satellite renal lesions and its surgical implication during nephron sparing surgery
Orit Raz, Sonia Mendlovic, Dan Leibovici, et al.
The Prostate
|
December 17, 2013
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel
Avivit Peer, Maya Gottfried, Victoria Sinibaldi, et al.
Future Oncology (London, England)
|
June 30, 2015
Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis
Eduard Vrdoljak, Martin Gore, Sophie Leyman, et al.
Epigenetics
|
January 20, 2010
A similar cell-specific pattern of HOXA methylation in normal and in cancer tissues
Ayelet Avraham, Judith Sandbank, Nirit Yarom, et al.
Clinical Genitourinary Cancer
|
May 11, 2019
Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial
Sergio Bracarda, Aristotelis Bamias, Jochen Casper, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 41) with videos related to
Sort By:
Page
of 5
Urology
|
March 1, 2008
Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer
Avishay Sella, Amnon Zisman, Svetlana Kovel, et al.
The Journal of Urology
|
January 17, 2002
Local anesthesia for prostate biopsy by periprostatic lidocaine injection: a double-blind placebo controlled study
Dan Leibovici, Amnon Zisman, Yoram I Siegel, et al.
Clinical Genitourinary Cancer
|
September 18, 2016
Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib
Avishay Sella, M Dror Michaelson, Ewa Matczak, et al.
Anti-Cancer Drugs
|
March 21, 2013
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone
Eduard Vrdoljak, Brian Rini, Manuela Schmidinger, et al.
International Journal of Cancer
|
March 13, 2012
Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients
Ayelet Avraham, Ronit Uhlmann, Aino Shperber, et al.
The Journal of Urology
|
September 18, 2007
The prevalence of malignancy in satellite renal lesions and its surgical implication during nephron sparing surgery
Orit Raz, Sonia Mendlovic, Dan Leibovici, et al.
The Prostate
|
December 17, 2013
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel
Avivit Peer, Maya Gottfried, Victoria Sinibaldi, et al.
Future Oncology (London, England)
|
June 30, 2015
Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis
Eduard Vrdoljak, Martin Gore, Sophie Leyman, et al.
Epigenetics
|
January 20, 2010
A similar cell-specific pattern of HOXA methylation in normal and in cancer tissues
Ayelet Avraham, Judith Sandbank, Nirit Yarom, et al.
Clinical Genitourinary Cancer
|
May 11, 2019
Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial
Sergio Bracarda, Aristotelis Bamias, Jochen Casper, et al.
Page
of 5